SOUTH KINGSTOWN – As the world population continues to age, age-related disorders, such as dementia and Alzheimer’s disease, are becoming more frequent.
A new study by Jaime Ross, assistant professor at the University of Rhode Island’s College of Pharmacy and at the George and Anne Ryan Institute for Neuroscience, is researching treatments for these disorders by looking at the role of epigenetics in cognitive decline.
ISO 9001:2026: A Practical Opportunity to Build for What’s Next
For Rhode Island manufacturers, ISO 9001 has been much more than a certificate on the…
Learn More
Ross’ study, funded by a $747,000 grant from the National Institutes of Health, will try to determine whether alterations in DNA packaging result in age-related cognitive decline and Alzheimer’s disease pathology, and if these changes are preventable or reversible.
“Results so far support the hypothesis that alterations to the epigenome can trigger aging acceleration in mammals,” Ross wrote in a project summary. “Taken together, this project will provide new valuable insights into the underlying mechanisms of the aging process – focusing on brain aging disorders – reveal potential biomarkers and highlight therapeutic strategies to improve the human condition.”
(UPDATE: Adds Ross’ position as assistant professor at URI’s George and Anne Ryan Institute for Neuroscience in the second paragraph.)
Claudia Chiappa is a PBN staff writer. You may contact her at Chiappa@PBN.com.
